| INHIBITORS | ORGANISM | UNIPROT ACCESSION NO. | COMMENTARY | LITERATURE | IMAGE |
| (2E,4E)-5-[(2S,3R,6S,8R,9S)-3-butyl-3-[(3-carboxypropanoyl)oxy]-8-(2-hydroxyethyl)-9-methyl-1,7-dioxaspiro[5.5]undec-2-yl]-3-methylpenta-2,4-dienoic acid | Homo sapiens | - | IC50 (ng/ml): value above 1000. Cell death inducibility of osteoclasts (microgram/ml): not determined | 691288 | 2D-image |
| (2E,4E)-5-[(2S,3R,6S,8R,9S)-3-butyl-3-[(3-carboxypropanoyl)oxy]-8-[(2E)-4-hydroxy-3-methylbut-2-en-1-yl]-9-methyl-1,7-dioxaspiro[5.5]undec-2-yl]-3-methylpenta-2,4-dienoic acid | Homo sapiens | - | IC50 (ng/ml): value above 1000. Cell death inducibility of osteoclasts (microgram/ml): not determined | 691288 | 2D-image |
| (2E,4E)-5-[(2S,3R,6S,8R,9S)-3-butyl-3-[(3-carboxypropanoyl)oxy]-8-[(2E)-4-[(3-carboxypropanoyl)oxy]-3-methylbut-2-en-1-yl]-9-methyl-1,7-dioxaspiro[5.5]undec-2-yl]-3-methylpenta-2,4-dienoic acid | Homo sapiens | - | IC50 (ng/ml): value above 1000. Cell death inducibility of osteoclasts (microgram/ml): above 15 | 691288 | 2D-image |
| (2E,4E)-5-[(2S,3R,6S,8R,9S)-3-butyl-3-[(3-carboxypropanoyl)oxy]-8-[(2E,4E)-6-hydroxy-3-methylhexa-2,4-dien-1-yl]-9-methyl-1,7-dioxaspiro[5.5]undec-2-yl]-3-methylpenta-2,4-dienoic acid | Homo sapiens | - | IC50 (ng/ml): 560.3. Cell death inducibility of osteoclasts (microgram/ml): not determined | 691288 | 2D-image |
| (2E,4E)-5-[(2S,3R,6S,8R,9S)-3-butyl-3-[(3-carboxypropanoyl)oxy]-8-[(2E,4E,6S,7S)-6,8-dihydroxy-3,7-dimethylocta-2,4-dien-1-yl]-9-methyl-1,7-dioxaspiro[5.5]undec-2-yl]-3-methylpenta-2,4-dienoic acid | Homo sapiens | - | IC50 (ng/ml): 22.9. Cell death inducibility of osteoclasts (microgram/ml): 6.31 | 691288 | 2D-image |
| (2E,4E)-6-[(2R,3S,6S,8S,9R)-9-butyl-8-[(1E,3E)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-[(3-carboxypropanoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undec-2-yl]-4-methylhexa-2,4-dienoic acid | Homo sapiens | - | IC50 (ng/ml): value above 1000. Cell death inducibility of osteoclasts (microgram/ml): not determined | 691288 | 2D-image |
| (2E,4S,5S,6E,8E)-10-[(2R,3S,6S,8S,9R)-9-butyl-8-[(1E,3E)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-3-methyl-9-[(methylsulfanyl)methoxy]-1,7-dioxaspiro[5.5]undec-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid | Homo sapiens | - | IC50 (ng/ml): 497.4. Cell death inducibility of osteoclasts (microgram/ml): 9.6 | 691288 | 2D-image |
| (2E,4S,5S,6E,8E)-10-[(2R,3S,6S,8S,9R)-9-butyl-8-[(1E,3E)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-hydroxy-3-methyl-1,7-dioxaspiro[5.5]undec-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid | Homo sapiens | - | IC50 (ng/ml): 94.6. Cell death inducibility of osteoclasts (microgram/ml): 11.5 | 691288 | 2D-image |
| (2E,4S,5S,6E,8E)-10-[(2R,3S,6S,8S,9R)-9-butyl-8-[(1E,3E)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-methoxy-3-methyl-1,7-dioxaspiro[5.5]undec-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid | Homo sapiens | - | IC50 (ng/ml): 57.9. Cell death inducibility of osteoclasts (microgram/ml): not determined | 691288 | 2D-image |
| (2E,4S,5S,6E,8E)-10-[(2R,3S,6S,8S,9R)-9-butyl-8-[(1E,3E)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-[(3-carboxypropanoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undec-2-yl]-4,5-dihydroxy-8-methyldeca-2,6,8-trienoic acid | Homo sapiens | - | IC50 (ng/ml): 14.4. Cell death inducibility of osteoclasts (microgram/ml): 1.01 | 691288 | 2D-image |
| (2E,4S,5S,6E,8E)-10-[(2R,3S,6S,8S,9R)-9-butyl-8-[(1E,3E)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-[(4-methoxy-4-oxobutanoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undec-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid | Homo sapiens | - | IC50 (ng/ml): 292.8. Cell death inducibility of osteoclasts (microgram/ml): 2.5 | 691288 | 2D-image |
| 1,10-phenanthroline | Ovis aries | - | - | 474 | 2D-image |
| 2',3'-dialdehyde of tRNAile | Escherichia coli | - | used to label the binding site for the 3'end of tRNA on the synthetase, incubation of the reagent with IleRS results in a rapid loss of tRNAIle aminoacylation and isoleucine-dependent isotopic ATP-PPi exchange activities | 706028 | - |
| 2,2'-Bipyridyl | Ovis aries | - | - | 474 | 2D-image |
| 2,3-dideoxy-adenosine-5-[(2S,3S)-2-amino-3-methylpentanoyl]-sulfamate | Escherichia coli | - | IC50: 0.0064 mM | 664321 | 2D-image |
| 2,3-Dihydro-5-epireveromycin A | Homo sapiens | - | IC50 (ng/ml): 58.3. Cell death inducibility of osteoclasts (microgram/ml): 0.82 | 691288 | 2D-image |
| 2,3-Dihydroreveromycin A | Homo sapiens | - | IC50 (ng/ml): 11.6. Cell death inducibility of osteoclasts (microgram/ml): 0.22 | 691288 | 2D-image |
| 2-deoxy-adenosine-5-[(2S,3S)-2-amino-3-methylpentanoyl]-sulfamate | Escherichia coli | - | IC50: 0.28 mM | 664321 | 2D-image |
| 2-iodo-L-isoleucine-NHSO2-AMP | Escherichia coli | - | highly potent inhibitor, hydrophobic interaction of the 2-substituent of the inhibitor with the adenine binding site of the enzyme | 650564 | 2D-image |
| 3'-Deoxyadenosine | Saccharomyces cerevisiae | - | i.e. cordycepin | 472 | 2D-image |
| 3-deoxy-adenosine-5-[(2S,3S)-2-amino-3-methylpentanoyl]-sulfamate | Escherichia coli | - | IC50: 0.035 mM | 664321 | 2D-image |
| 5'-N-[N-(L-isoleucyl)sulfamoyl]adenosine | Thermus thermophilus | - | non-hydrolyzable analogue of the reaction intermediate Ile-AMP | 652205 | 2D-image |
| 5-acetyl-Reveromycin A | Homo sapiens | - | IC50 (ng/ml): value above 1000. Cell death inducibility of osteoclasts (microgram/ml): 0.46 | 691288 | 2D-image |
| 5-Epireveromycin A | Homo sapiens | - | IC50 (ng/ml): 378.3. Cell death inducibility of osteoclasts (microgram/ml): 21.5 | 691288 | 2D-image |
| 5-methoxy-Reveromycin A | Homo sapiens | - | IC50 (ng/ml): 374. Cell death inducibility of osteoclasts (microgram/ml): above 15 | 691288 | 2D-image |
| 5-O-succinyl-Spirofungin A | Homo sapiens | - | IC50 (ng/ml): value above 1000. Cell death inducibility of osteoclasts (microgram/ml): 12.4 | 691288 | 2D-image |
| 5-tert-butyl-dimethylsilyl-Reveromycin A | Homo sapiens | - | IC50 (ng/ml): value above 1000. Cell death inducibility of osteoclasts (microgram/ml): 5.9 | 691288 | 2D-image |
| 7-[3-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]amino]propanoyl-2,4a,5,6,7,7a-hexahydro-2-methyl-1H-cyclopenta[c]pyridine-4-carboxamide | Rattus norvegicus | - | derivative of SB-203207, 10% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[4-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]amino]butanoyl-2,4a,5,6,7,7a-hexahydro-2-methyl-1H-cyclopenta[c]pyridine-4-carboxamide | Rattus norvegicus | - | derivative of SB-203207, 18% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[4-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]amino]butanoyl-2,4a,5,6,7,7a-hexahydro-2-methyl-1H-cyclopenta[c]pyridine-4-carboxamide | Staphylococcus aureus | - | derivative of SB-203207, 26% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[[(2S,3S)-2-amino-3-methyl-1-oxopentyl]amino]acetyloxy-2,4a,5,6,7,7a-hexahydro-2-methyl-1H-cyclopenta[c]pyridine-4-carboxamide | Rattus norvegicus | - | derivative of SB-203207, 17% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[[(2S,3S)-2-amino-3-methyl-1-oxopentyl]amino]sulfonylacetyloxy-2,4a,5,6,7,7a-hexahydro-2-methyl-1H-cyclopenta[c]pyridine-4-carboxamide | Rattus norvegicus, Staphylococcus aureus | - | - | 650527 | 2D-image |
| 7-[[(2S,3S)-2-amino-3-methyl-1-oxopentyl]amino]sulfonylacetyloxy-2,4a,5,6,7,7a-hexahydro-2-methyl-1H-cyclopenta[c]pyridine-4-carboxylic acid methyl ester | Rattus norvegicus | - | derivative of SB-203207, 49% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[[(2S,3S)-2-amino-3-methyl-1-oxopentyl]amino]sulfonylacetyloxy-2,4a,5,6,7,7a-hexahydro-2-methyl-1H-cyclopenta[c]pyridine-4-carboxylic acid methyl ester | Staphylococcus aureus | - | derivative of SB-203207, 31% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[[(2S,3S)-2-amino-3-methyl-1-oxopentyl]amino]sulfonylacetyloxy-4,4a,5,6,7,7a-hexahydro-1-methyl-1H-cyclopenta[b]pyridine-3-carboxylic acid methyl ester | Rattus norvegicus | - | derivative of SB-203207, 46% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[[(2S,3S)-2-amino-3-methyl-1-oxopentyl]amino]sulfonylacetyloxy-4,4a,5,6,7,7a-hexahydro-1-methyl-1H-cyclopenta[b]pyridine-3-carboxylic acid methyl ester | Staphylococcus aureus | - | derivative of SB-203207, 34% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[[(S)-2-amino-1-oxo-5-thiahexyl]amino]sulfonylacetyloxy-2,4a,5,6,7,7a-hexahydro-2-methyl-1H-cyclopenta[c]pyridine-4-carboxamide | Rattus norvegicus | - | derivative of SB-203207, 31% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[[(S)-2-amino-1-oxo-5-thiahexyl]amino]sulfonylacetyloxy-2,4a,5,6,7,7a-hexahydro-2-methyl-1H-cyclopenta[c]pyridine-4-carboxamide | Staphylococcus aureus | - | derivative of SB-203207, 38% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[[(S)-2-amino-1-oxo-hexyl]amino]sulfonylacetyloxy-2,4a,5,6,7,7a-hexahydro-2-methyl-1H-cyclopenta[c]pyridine-4-carboxamide | Rattus norvegicus | - | derivative of SB-203207, 17% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[[(S)-2-amino-1-oxo-hexyl]amino]sulfonylacetyloxy-2,4a,5,6,7,7a-hexahydro-2-methyl-1H-cyclopenta[c]pyridine-4-carboxamide | Staphylococcus aureus | - | derivative of SB-203207, 46% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[[(S)-2-amino-3-methyl-1-oxobutyl]amino]sulfonylacetyloxy-2,4a,5,6,7,7a-hexahydro-2-methyl-1H-cyclopenta[c]pyridine-4-carboxylic acid methyl ester | Rattus norvegicus | - | derivative of SB-203207, 31% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[[(S)-2-amino-3-methyl-1-oxobutyl]amino]sulfonylacetyloxy-2,4a,5,6,7,7a-hexahydro-2-methyl-1H-cyclopenta[c]pyridine-4-carboxylic acid methyl ester | Staphylococcus aureus | - | derivative of SB-203207, 38% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[[(S)-2-amino-3-methyl-1-oxobutyl]amino]sulfonylacetyloxy-4,4a,5,6,7,7a-hexahydro-1-methyl-1H-cyclopenta[b]pyridine-3-carboxylic acid methyl ester | Rattus norvegicus | - | derivative of SB-203207, 33% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[[(S)-2-amino-3-methyl-1-oxobutyl]amino]sulfonylacetyloxy-4,4a,5,6,7,7a-hexahydro-1-methyl-1H-cyclopenta[b]pyridine-3-carboxylic acid methyl ester | Staphylococcus aureus | - | derivative of SB-203207, 10% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[[(S)-2-amino-3-methyl-1-oxopentyl]amino]sulfonylacetyloxy-4,4a,5,6,7,7a-hexahydro-1-methyl-1H-cyclopenta[b]pyridine-3-carboxylic acid methyl ester | Rattus norvegicus | - | derivative of SB-203207, 13% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[[(S)-2-amino-3-methyl-1-oxopentyl]amino]sulfonylacetyloxy-4,4a,5,6,7,7a-hexahydro-1-methyl-1H-cyclopenta[b]pyridine-3-carboxylic acid methyl ester | Staphylococcus aureus | - | derivative of SB-203207, 15% inhibition at 0.1 mM | 650527 | 2D-image |
| 7-[[(S)-2-amino-4-methyl-1-oxopentyl]amino]sulfonylacetyloxy-2,4a,5,6,7,7a-hexahydro-2-methyl-1H-cyclopenta[c]pyridine-4-carboxylic acid methyl ester | Rattus norvegicus | - | derivative of SB-203207, 14% inhibition at 0.1 mM | 650527 | 2D-image |
| 8-Aminoadenosine | Saccharomyces cerevisiae | - | - | 472 | 2D-image |
| 8-azidoadenosine 5'-triphosphate | Saccharomyces cerevisiae | - | - | 472 | 2D-image |
| adenosine-5-[(2S,3S)-2-amino-3-methylpentanoyl]-sulfamate | Escherichia coli | - | IC50: 0.000265 mM | 664321 | 2D-image |
| bromometyl ketone derivative of L-isoleucine | Escherichia coli | - | labeling reagent | 706028 | - |
| bromometyl ketone derivative of norleucine | Escherichia coli | - | labeling reagent | 706028 | - |
| bromometyl ketone derivative of phenylalanine | Escherichia coli | - | labeling reagent | 706028 | - |
| bromometyl ketone derivative of valine | Escherichia coli | - | labeling reagent | 706028 | - |
| Chymotrypsin | Staphylococcus aureus | - | proteolytic inactivation patterns, bound Ile-AMP or inhibitors isoleucinol adenylate and pseudomonic acid protect, 50fold higher concentration is needed for digestion of Ile-AMP-enzyme complex than for the free enzyme at 37°C | 651905 | - |
| diethyl dicarbonate | Escherichia coli | - | - | 706028 | 2D-image |
| diphosphate | Escherichia coli | - | partly inhibits the binding of tRNA | 454 | 2D-image |
| ester analogues of isoleucyl adenylate | Escherichia coli | - | with or without cyclic substitutents at the adenine moiety | 650559 | 2D-image |
| ethyl monate-A | Staphylococcus aureus | - | - | 651904 | 2D-image |
| Furanomycin | Escherichia coli | - | - | 471 | 2D-image |
| hydroxamate analogues of isoleucyl adenylate | Escherichia coli | - | with or without cyclic substitutents at the adenine moiety | 650559 | 2D-image |
| Ile-NHSO2-AMP | Staphylococcus aureus | - | non-hydrolyzable reaction intermediate analogue, slow-tight binding, competitive and inhibition mechanism, reversible | 651904 | 2D-image |
| Ile-ol-AMP | Staphylococcus aureus | - | - | 651903 | 2D-image |
| isoleucinol adenylate | Staphylococcus aureus | - | determination of binding structures, bound inhibitor protects against proteolytic inactivation by trypsin or chymotrypsin and specifically alters the proteolytic cleavage pattern | 651905 | 2D-image |
| isoleucinyl adenylate | Staphylococcus aureus | - | i.e. Ile-ol-AMP, nonhydrolyzable reaction intermediate analogue, competitive with respect to both ATP and Ile | 651903 | 2D-image |
| isoleucinyl-adenylate | Staphylococcus aureus | - | i.e. Ile-ol-AMP, non-hydrolyzable reaction intermediate analogue, slow-tight binding, competitive and inhibition mechanism, reversible | 651904 | 2D-image |
| isoleucyl isovanilloids | Escherichia coli | - | e.g. the isovanillic hydroxamate and amide analogue | 650560 | 2D-image |
| isoleucyl sulfamate analogues | Escherichia coli | - | - | 650564 | 2D-image |
| isoleucyl vanilloids | Escherichia coli | - | e.g. the vanillic hydroxamate with a phenolic hydoxyl at the para-position | 650560 | 2D-image |
| isoleucyl-N'-adenosyl-N'-hydroxy sulfamide | Escherichia coli | - | - | 650564 | 2D-image |
| isoleucyl-N'-adenosyloxy sulfamide | Escherichia coli | - | - | 650564 | 2D-image |
| K+ | Thermus thermophilus | - | - | 466 | 2D-image |
| muciproin | Staphylococcus aureus | - | - | 652205, 653886 | 2D-image |
| muciproin | Thermus thermophilus | - | inhibition by blockage of the binding site of high energy intermediate Ile-AMP, the inhibitor contains a moiety that morphologically resembles the hydrophobic side chain of L-isoleucine, recognition is mediated by Pro46, Trp518, and Trp558 | 652205 | 2D-image |
| mupirocin | Staphylococcus aureus | P41972 | a specific inhibitor of IleRS, which binds in the vicinity of an ATP-binding subsite, and is a bifunctional inhibitor with characteristics of both isoleucine and ATP, i.e. an analogue of isoleucyladenylate, binding structure, overview, mupirocin resistance is phenotypically divided into two groups: low-level and high-level. Highlevel resistance is mediated by a plasmid containing the ileS-2 gene that encodes a distinct isoleucyl-tRNA synthetase enzyme, whereas low-level resistance usually results from alteration of the native IleS as a consequence of spontaneous mutations in the ileS gene | 675256 | 2D-image |
| mupirocin | Staphylococcus aureus | - | - | 693190 | 2D-image |
| mupirocin | Salmonella enterica | - | Mup, an isoleucyl-adenylate analogue that inhibits the essential enzyme, isoleucyl-tRNA synthetase | 715118 | 2D-image |
| mupirocin | Plasmodium falciparum | - | irreversible inhibition, inhibits development of invasion-competent parasites in the second asexual cycle, delayed death phenotype | 716781 | 2D-image |
| Na+ | Thermus thermophilus | - | - | 466 | 2D-image |
| Pseudomonic acid | Escherichia coli | - | bifunctional inhibitor with characteristics of both isoleucine and ATP | 447 | 2D-image |
| Pseudomonic acid | Saccharomyces cerevisiae | - | pseudomonic acid A: Saccharomyces cerevisiae enzyme is 10000 times less sensitive than Escherichia coli enzyme | 457 | 2D-image |
| Pseudomonic acid | Methanothermobacter thermautotrophicus | - | - | 459 | 2D-image |
| Pseudomonic acid | Escherichia coli | - | - | 471 | 2D-image |
| Pseudomonic acid | Methanothermobacter thermautotrophicus | - | wild-type enzyme strongly inhibited, pseudomonic acid-resistant mutant only marginally | 475 | 2D-image |
| Pseudomonic acid | Staphylococcus aureus | - | forms a non-hydrolyzable reaction intermediate analogue, competitive inhibition | 651904 | 2D-image |
| Pseudomonic acid | Staphylococcus aureus | - | competitive, determination of binding structures, bound inhibitor protects against proteolytic inactivation by trypsin or chymotrypsin and specifically alters the proteolytic cleavage pattern | 651905 | 2D-image |
| Pseudomonic acid | Pseudomonas fluorescens | Q8L1B1 | i.e. muciproin | 652415 | 2D-image |
| purineriboside | Saccharomyces cerevisiae | - | i.e. nebularin | 472 | 2D-image |
| pyridoxal 5'-diphospho-5'-adenosine | Escherichia coli | - | affinity labeling reagent for the ATP-binding site, incubation of the reagent with IleRS results in a rapid loss of tRNAIle aminoacylation and isoleucine-dependent isotopic ATP-PPi exchange activities | 706028 | 2D-image |
| Reveromycin A | Homo sapiens | - | IC50 (ng/ml): 2.95. Cell death inducibility of osteoclasts (microgram/ml): 0.06 | 691288 | 2D-image |
| Reveromycin A 1-methyl ester | Homo sapiens | - | IC50 (ng/ml): 211. Cell death inducibility of osteoclasts (microgram/ml): 2 | 691288 | 2D-image |
| Reveromycin A 24-methyl ester | Homo sapiens | - | IC50 (ng/ml): value above 1000. Cell death inducibility of osteoclasts (microgram/ml): 3.1 | 691288 | 2D-image |
| Reveromycin B | Homo sapiens | - | IC50 (ng/ml): value above 1000. Cell death inducibility of osteoclasts (microgram/ml): above 15 | 691288 | 2D-image |
| SB-203207 | Rattus norvegicus, Staphylococcus aureus | - | anti-infective agent, isolated from Streptomyces NCIMB 40513, analogous to the reaction intermediate | 650527 | 2D-image |
| SB-205952 | Staphylococcus aureus | - | a semisynthetic analogue of monic acid, possesing a nitrofuryl chromophore | 651904 | 2D-image |
| SB-205952 | Staphylococcus aureus | - | a semisynthetic analogue of monic acid | 651905 | 2D-image |
| spermine | Escherichia coli | - | catalyzes ATP-diphosphate exchange, no inhibition of specific aminoacylation of tRNAIle | 463 | 2D-image |
| Spirofungin A | Homo sapiens | - | IC50 (ng/ml): 564.5. Cell death inducibility of osteoclasts (microgram/ml): above 30 | 691288 | 2D-image |
| Spirofungin B | Homo sapiens | - | IC50 (ng/ml): value above 1000. Cell death inducibility of osteoclasts (microgram/ml): above 30 | 691288 | 2D-image |
| thiaisoleucine | Plasmodium falciparum | - | directly competes with isoleucine for a target, irreversible inhibition, inhibits ring-stage parasites in development | 716781 | - |
| tRNA | Escherichia coli | - | partly inhibits the binding of diphosphate | 454 | 2D-image |
| Trypsin | Staphylococcus aureus | - | proteolytic inactivation patterns, bound Ile-AMP or inhibitors isoleucinol adenylate and pseudomonic acid protect, 50fold higher concentration is needed for digestion of Ile-AMP-enzyme complex than for the free enzyme at 37°C | 651905 | - |
| Mg2+ | Rattus norvegicus | - | in presence of 50 mM K+ and in absence of polyamines, the optimal Mg2+ concentration for Ile-tRNA formation is 1 mM, an increase in Mg2+ concentration markedly inhibits | 470 | 2D-image |
| additional information | Rattus norvegicus, Staphylococcus aureus | - | diverse analogues of SB-203207 are not inhibitory, overview | 650527 | - |
| additional information | Escherichia coli | - | inhibition mechanism and structural determinants | 650559 | - |
| additional information | Escherichia coli | - | the ribose of ATP/AMP can be substituted by its biosteres acyclic amide, hydroxamate, dihydroisooxazole, and dihydrooxazole, binding structure, overview | 650560 | - |
| additional information | Pseudomonas fluorescens | Q8L1B1 | no inhibition of isozyme IleRS-R2 by pseudomonic acid, i.e. muciproin | 652415 | - |